Mycograb (efungumab)
- Region
- 🇪🇺 EU
- Active substance
- efungumab
- Company
- NeuTec Pharma plc
- Status
- Refused
- Therapeutic area
- Candidiasis
- CHMP opinion
- Tue 20 Mar 2007
- Application
- EMEA/H/C/000658
- ATC
- J02
- Official record
- www.ema.europa.eu
Indication
Treatment of invasive candidiasis in adult patients, in combination with amphotericin B or a lipid formulation of amphotericin B.
Regulatory milestones
No milestones recorded in the last year.
Follow Mycograb
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.